Related Experiment Video
Updated: Jun 29, 2026
08:34
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
[Anticoagulation in pulmonary arterial hypertension]
1Zentrum für Pulmonale Hypertonie, Thoraxklinik Heidelberg, Amalienstrasse 5, Heidelberg. ekkehard.gruenig@thoraxklinik-heidelberg.de
Hamostaseologie
|October 7, 2008
Summary
Pulmonary arterial hypertension (PAH) involves blood clotting due to vascular changes. Anticoagulant therapy, like Warfarin, shows promise, but more research is needed.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pulmonary Medicine
Context:
- Pulmonary arterial hypertension (PAH) is characterized by pulmonary microvasculopathy.
- A procoagulant, prothrombotic, and antifibrinolytic shift occurs in the pulmonary vascular microenvironment in PAH.
- Elevated levels of antiphospholipid antibodies, platelet aggregators, adhesion molecules, antifibrinolytic enzymes, and prothrombotic cytokines are observed in PAH patients.
Purpose:
- To review current data and guidelines on anticoagulation in pulmonary arterial hypertension (PAH).
- To explore the rationale for anticoagulation therapy in PAH based on observed thrombogenic mechanisms.
Summary:
- Thrombosis and thromboembolism are consequences of pulmonary microvasculopathy in PAH.
- Warfarin has demonstrated improved prognosis in uncontrolled studies of idiopathic and other forms of PAH.
- Prospective randomized studies evaluating anticoagulants in PAH treatment are currently lacking.
Impact:
- Highlights the need for further investigation into anticoagulation as a treatment for PAH.
- Provides a summary of existing evidence and clinical guidelines for managing thrombosis in PAH.
- Emphasizes the potential of anticoagulation to improve outcomes in patients with pulmonary arterial hypertension.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...